[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352065-105":59,"doc-detail-352065-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prognostic-significance-of-androgen-receptor-expression-in-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy-a-retrospective-cohort-study","Prognostic significance of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy - A retrospective cohort study","","The androgen receptor (AR) is an emerging biomarker in breast cancer, but its prognostic relevance during neoadjuvant chemotherapy remains uncertain, especially for Caucasus populations with limited data. A retrospective cohort study of 132 women with stage II–III breast cancer evaluated AR expression patterns and their relationships to pathological response and disease-free survival using chi-square tests, Kaplan–Meier curves, and Cox regression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-significance-of-androgen-receptor-expression-in-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy-a-retrospective-cohort-study/352065/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-significance-of-androgen-receptor-expression-in-breast-cancer-patients-undergoing-neoadjuvant-chemotherapy-a-retrospective-cohort-study/352065.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main goal?","Question",{"text":112,"@type":113},"To assess whether androgen receptor (AR) expression is associated with pathological response and disease-free survival in stage II–III breast cancer patients receiving neoadjuvant chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was AR expression measured and categorized?",{"text":117,"@type":113},"AR expression patterns were categorized as negative, weak, moderate, or strong.",{"name":119,"@type":110,"acceptedAnswer":120},"What relationship was found between AR expression and disease-free survival?",{"text":121,"@type":113},"While dichotomized AR expression did not significantly predict DFS, Cox regression across all four AR categories showed a significant reduction in recurrence risk; moderate-to-strong AR expression also showed a higher 2-year DFS rate among non-pCR patients.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352065,1791266251,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","®  \n Observational Study   \nPrognostic significance of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy  \nA retrospective cohort study  \nAltay Aliyev, MDa , Adila Adilli, MDb , Aydan Ismayilsoy, MDa , Farida Aghayarli, MDa , Iqbal Babazade, MDa , Arturan Ibrahimli, MDc , Ceyhun Isayev, MDd , Thomas Karn, MD, PhDe , Bahar Gasimli, MDe ,  \nKhayal Gasimli, MD, PhDe ,*  \n\n| Abstract\u003Cbr>The androgen receptor (AR) is an emerging biomarker in breast cancer (BC), yet its prognostic relevance in patients undergoing neoadjuvant chemotherapy (NACT) remains inconclusive. While most studies focus on Western populations, data from the Caucasus are scarce. Given regional differences in tumor biology and treatment access, evaluating AR’s clinical significance in these populations is crucial. This study aimed to investigate the association between AR expression, pathological response, and disease-free survival (DFS) in stage II to III BC patients receiving NACT. A retrospective cohort study was conducted on 132 female BC patients treated with NACT at Bonadea Hospital. AR expression patterns were categorized as negative, weak, moderate, or strong. Statistical analyses included chi-square tests, Kaplan–Meier survival analysis, and univariate Cox regression to evaluate associations between AR expression and clinicopathological features, pathological complete response (pCR), and DFS. The median age at diagnosis was 47 years. Invasive ductal carcinoma accounted for 91.1% of cases, with 50.0% of tumors gradedas II or III. pCR was achieved in 28.6% of patients. Moderate-to-strong AR expression was observed in 15% of cases and was associated with a significantly lower Ki-67 index (P = .047) . Although dichotomized AR expression did not significantly predict DFS (hazard ratio [HR]: 0.35, 95% confidence interval [CI]: 0.08–1.47, P = . 151), Cox regression using all 4 AR categories revealed a significant reduction in recurrence risk (HR = 0.384, 95% CI: 0.160–0.918, P = .031) . In multivariable model adjusting for estrogen receptor, human epidermal growth factor receptor 2, and Ki-67 expression, moderate-to-strong AR expression remained the most influential prognostic factor, although the association did not reach statistical significance (adjusted HR: 0.31, 95% CI: 0.07–1.41, P = . 129; concordance index = 0.83) . Among patients with residual disease (non-pCR), moderate-to-strong AR expression was associated with a higher 2-year DFS rate (90 .9% vs 46.4%, P = .089) . Sensitivity analysis demonstrated no evidence of selection bias related to AR data availability, as 2-year DFS was comparable between patients with and without available AR assessment (76 . 1% vs 71.6%, log-rank P = .975) . Moderate-to-strong AR expression may be associated with improved DFS in patients treated with NACT, especially in those with incomplete pathological response. These findings highlight the potential of AR as a prognostic biomarker and therapeutic target, warranting validation in prospective studies.\u003Cbr>Abbreviations: AR = androgen receptor, BC = breast cancer, CI = confidence interval, cN = clinical nodal, CNB = core needle biopsy, cT = clinical tumor, DFS = disease-free survival, ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, HR = hazard ratio, IHC = immunohistochemical, NACT = neoadjuvant chemotherapy, OS = overall survival, pCR = pathological complete response, PR = partial response, TNBC = triple-negative breast cancer. |\n| --- |\n| Keywords: androgen receptor, breast cancer, neoadjuvant chemotherapy, disease-free survival, prognostic biomarker |\n\n1. Introduction  \nBreast cancer (BC) remains the most frequently diagnosed malignancy and a leading cause of cancer-related mortality  \namong women globally.[1] Neoadjuvant chemotherapy (NACT) has become an integral component of the treatment paradigm for patients with locally advanced BC, facilitating tumor downstaging and enhancing the feasibility of breast","cbCaijlPF8humkAK","https://ap.wps.com/l/cbCaijlPF8humkAK","pdf",1773132,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What was the study’s main goal?\",\"answer\":\"To assess whether androgen receptor (AR) expression is associated with pathological response and disease-free survival in stage II–III breast cancer patients receiving neoadjuvant chemotherapy.\"},{\"question\":\"How was AR expression measured and categorized?\",\"answer\":\"AR expression patterns were categorized as negative, weak, moderate, or strong.\"},{\"question\":\"What relationship was found between AR expression and disease-free survival?\",\"answer\":\"While dichotomized AR expression did not significantly predict DFS, Cox regression across all four AR categories showed a significant reduction in recurrence risk; moderate-to-strong AR expression also showed a higher 2-year DFS rate among non-pCR patients.\"}]","Prognostic significance of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy - A retrospective cohort study | PDF",1790097521,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef07e05ff9d233f3276a5cf3691ee838.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9888cf5e0cc71e04af43213a976898f8.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ea8e2f3df2d044a8b3b3039404e07e87.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b7ce682514cd1746150c6ef9dcf39f3.webp",980,1306]